Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Trial Identifier: 3475-177
Sponsor: MSD
Start Date: November 2015
Primary Completion Date: February 2021
Study Completion Date: July 2023
Condition: Colorectal Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary - EMEA Swedish
Results Plain Language Summary - NA French Canadian
Results Plain Language Summary - EMEA Norwegian
Results Plain Language Summary - LA Portuguese
Results Plain Language Summary - EMEA Sesotho
Results Plain Language Summary - EMEA Finnish
Results Plain Language Summary - EMEA Spanish
Results Plain Language Summary - EMEA Xhosa
Results Plain Language Summary - EMEA Italian
Results Plain Language Summary - English
Results Plain Language Summary - EMEA Swedish
Results Plain Language Summary - EMEA Zulu
Results Plain Language Summary - EMEA French (Belgium)
Results Plain Language Summary - EMEA Dutch (Belgium)
Results Plain Language Summary - EMEA Danish
Results Plain Language Summary - EMEA French
Results Plain Language Summary - EMEA Afrikaans
Results Plain Language Summary - EMEA German
Results Plain Language Summary - EMEA German (Belgium)
Results Plain Language Summary - EMEA Dutch (Netherlands)

Trial Locations

No locations posted.